{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T15:34:34Z","timestamp":1774712074021,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.prro.2020.06.004","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T21:51:08Z","timestamp":1592430668000},"page":"e90-e97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dosimetric Predictors of Genitourinary Toxicity From a Phase I Trial of Prostate Bed Stereotactic Body Radiation Therapy"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-4074","authenticated-orcid":false,"given":"Ashwin","family":"Shinde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhui","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-7446","authenticated-orcid":false,"given":"Sagus","family":"Sampath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2020.06.004_bib1","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prro.2020.06.004_bib2","series-title":"NCCN Guidelines: Prostate Cancer","year":"2018"},{"key":"10.1016\/j.prro.2020.06.004_bib3","first-page":"14","article-title":"Management of biochemically recurrent prostate cancer after local therapy: Evolving standards of care and new directions","volume":"11","author":"Paller","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.prro.2020.06.004_bib4","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.2008.18.9563","article-title":"Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02\/AUO AP 09\/95","volume":"27","author":"Wiegel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2020.06.004_bib5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.adro.2017.08.004","article-title":"Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy","volume":"2","author":"Jensen","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2020.06.004_bib6","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1200\/JCO.2005.01.867","article-title":"Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy","volume":"23","author":"Stephenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2020.06.004_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijrobp.2011.10.069","article-title":"The timing of salvage radiotherapy after radical prostatectomy: A systematic review","volume":"84","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2020.06.004_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijrobp.2010.10.026","article-title":"Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: Technique, early toxicity, and PSA response","volume":"82","author":"Jabbari","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2020.06.004_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.prro.2017.11.008","article-title":"Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?","volume":"8","author":"Gonzalez-Motta","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2020.06.004_bib10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is alpha\/beta for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2020.06.004_bib11","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2020.06.004_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijrobp.2019.11.005","article-title":"Stereotactic body radiation therapy to the prostate bed: results of a phase 1 dose escalation trial","volume":"106","author":"Sampath","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2020.06.004_bib13","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer","volume":"29","author":"Boike","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2020.06.004_bib14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2009.02.006","article-title":"Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2020.06.004_bib15","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.1016\/j.ijrobp.2017.06.1186","article-title":"Dose constraints for the bladder and urethra for stereotactic body radiation therapy to the prostate","volume":"99","author":"Jones","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.prro.2020.06.004_bib16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","article-title":"Shortening the timeline of pediatric phase I trials: The rolling six design","volume":"26","author":"Skolnik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2020.06.004_bib18","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?","volume":"154","author":"Barry","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2020.06.004_bib19","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.eururo.2007.08.042","article-title":"The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: The Krimpen Study","volume":"53","author":"Bosch","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2020.06.004_bib20","doi-asserted-by":"crossref","first-page":"E921","DOI":"10.5489\/cuaj.3057","article-title":"Evaluation of risk factors and treatment options in patients with ureteral stricture disease at a single institution","volume":"9","author":"Tran","year":"2015","journal-title":"J Can Urol Assoc"},{"key":"10.1016\/j.prro.2020.06.004_bib21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: Survival and toxicity endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2020.06.004_bib22","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.ijrobp.2018.07.191","article-title":"Patient and dosimetric predictors of genitourinary and bowel quality of life after prostate SBRT: Secondary analysis of a multi-institutional trial","volume":"102","author":"Wang","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2020.06.004_bib23","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s40265-015-0443-5","article-title":"A Practical approach to the management of radiation-induced hemorrhagic cystitis","volume":"75","author":"Liem","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.prro.2020.06.004_bib24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.clon.2018.05.001","article-title":"An investigation of dosimetric correlates of acute toxicity in prostate stereotactic body radiotherapy: Dose to urinary trigone is associated with acute urinary toxicity","volume":"30","author":"Henderson","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.prro.2020.06.004_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.prro.2012.08.004","article-title":"Late toxicity after intensity modulated and image guided radiation therapy for localized prostate cancer and post-prostatectomy patients","volume":"3","author":"Hunter","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2020.06.004_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13014-017-0839-3","article-title":"Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: Six- year outcomes and predictors of late toxicity","volume":"12","author":"Jolnerovski","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2020.06.004_bib27","first-page":"31","article-title":"Correlation between urinary dose and delayed radiation cystitis after 78 Gy intensity-modulated radiotherapy for high-risk prostate cancer: A 10-year follow-up study of genitourinary toxicity in clinical practice","volume":"6","author":"Inokuchi","year":"2017","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.prro.2020.06.004_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197757","article-title":"Development of a prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients","volume":"13","author":"Schaake","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.prro.2020.06.004_bib29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijrobp.2018.12.047","article-title":"Phase 1 trial of SBRT to the prostate fossa after prostatectomy","volume":"104","author":"Ballas","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2020.06.004_bib30","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.ijrobp.2018.08.052","article-title":"Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: The NRG Oncology\/RTOG 0534 SPPORT Trial","volume":"102","author":"Pollack","year":"2018","journal-title":"Int J Radiat Oncol"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850020301594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850020301594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:22:45Z","timestamp":1761819765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850020301594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1879850020301594"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2020.06.004","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosimetric Predictors of Genitourinary Toxicity From a Phase I Trial of Prostate Bed Stereotactic Body Radiation Therapy","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2020.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}